Pharma & biotech
24 large-cap companies along a 6-stage value chain, researched and connected to their suppliers and customers. rejo measures this industry in: trial readouts, PDUFA dates, scripts, net price, pipeline, patent cliffs.
The value chain
1
Discovery
- No covered company at this stage
2
Clinical trials
- AbbVie
- Amgen
- Gilead Sciences
- Vertex Pharmaceuticals
- Moderna
- Regeneron Pharmaceuticals
3
Regulatory
- No covered company at this stage
4
Manufacturing
- No covered company at this stage
5
Launch & market access
- Eli Lilly
- Johnson & Johnson
- Merck &
- Roche
- Novartis
- AstraZeneca
6
Payers
- No covered company at this stage
Largest covered companies
| Eli Lilly | LLY | Launch & market access |
| Johnson & Johnson | JNJ | Launch & market access |
| AbbVie | ABBV | Clinical trials |
| Merck & | MRK | Launch & market access |
| Roche | RHHBY | Launch & market access |
| Novartis | NVS | Launch & market access |
| AstraZeneca | AZN | Launch & market access |
| Amgen | AMGN | Clinical trials |
| Gilead Sciences | GILD | Clinical trials |
| Novo Nordisk | NVO | Launch & market access |
| Pfizer | PFE | Launch & market access |
| Vertex Pharmaceuticals | VRTX | Clinical trials |
What rejo does for pharma & biotech investors
- A desk, brief and idea engine scoped to pharma & biotech and organised by its value chain.
- The Transmission Desk: every print and supplier event in the industry, followed to the companies it reaches.
- Supply webs for each company, including private suppliers, and the suppliers the industry shares.
- Channel checks against consensus and prep sheets before each print.
- A KPI board in the industry's own measures: trial readouts, PDUFA dates, scripts, net price.